Dr. Carlos Aguilar is an expert on the pathophysiology, treatment, and management of dyslipidemias and type 2 diabetes in Mexico. He is a surgeon specializing in Internal Medicine and Endocrinology and holds a doctorate in Medical Research. His main contributions include: participating in the identification of new genes involved in the pathophysiology of Familial Combined Hyperlipidemia; being part of the team that conducted the first genome-wide study to identify the genetic variants that modulate plasma lipid levels in Mexicans; and helping identify the R230C variant of the ABC-A1 transporter (a variant specific to Amerindian populations) as a determinant of HDL cholesterol concentrations in Mexicans, among others.

Since 1996, he has been deputy chief of the Department of Endocrinology and Metabolism of the National Institute of Medical Sciences and Nutrition (Mexico) and has been coordinator of the
Ethics Committee of the National Institute of Medical Sciences and Nutrition since 2012. He is also a member of the National Academy of Medicine and has held positions such as director of examinations of the Mexican Board of Endocrinology and president of the Mexican Society of Nutrition and Endocrinology. 

Carlos Aguilar is a Level III researcher with the National System of Researchers in Mexico and a Level F researcher with the National Institutes of Health in the U.S. His scientific output is prolific, with more than 540 articles published in peer-reviewed and/or indexed journals and 66,711 citations. His research focuses on the peculiarities of metabolic diseases in Mexican mestizos, such as the pathophysiology of primary dyslipidemias, the epidemiology of type 2 diabetes, the development of predictive models for type 2 diabetes and its comorbidities, and the characterization of the mechanisms by which certain genetic variants are associated with type 2 diabetes. He received Mexico’s National Science Award in 2018.

Carlos Aguilar joined Tecnológico de Monterrey as Distinguished Visiting Professor in Epidemiology at the School of Medicine and Health Sciences.

• Doctorate in Medical Research, Escuela Superior de Medicina, Instituto Politécnico Nacional
• Research stay at the Division of Atherosclerosis and Lipid Research, Washington University
• Specialty in Endocrinology, Instituto Nacional de la Nutrición
• Specialty in Internal Medicine, Instituto Nacional de la Nutrición
• Medical Surgeon, Universidad Nacional Autónoma de México (UNAM)

• Rojas-Martínez R, Escamilla-Nuñez C, Aguilar-Salinas CA, Castro-Porras L, Romero-Martínez M, Lazcano-Ponce E. Trends in the mortality of diabetes in Mexico from 1998 to 2022: a joinpoint regression and age-period-cohort effect analysis. Public Health. 2023 Dec 5;226:128-137. doi: 10.1016/j.puhe.2023.10.038
• Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, Rivera JA, Romero-Martinez M, Barquera S, Barrientos-Gutiérrez T. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Publica Mex. 2023 Jun 13;65:s163-s168. doi: 10.21149/14832
• Rojas-Martínez R, Escamilla-Núñez C, Castro-Porras L, Basto-Abreu A, Barrientos-Gutiérrez T, Romero-Martínez M, Aguilar-Salinas C. Tamizaje, prevalencia, diagnóstico previo, tratamiento y control de hipertensión, hipercolesterolemia y diabetes en adultos mexicanos. Ensanut 2022. Salud Publica Mex. 2023 Nov 13;65(6, nov-dic):685-696. doi: 10.21149/15060
• Rivera-Alcántara JA, Esparza-Hurtado N, Galán-Ramírez GA, Cruz-Bautista I, Mehta R, Aguilar-Salinas CA, Martagon AJ. A systematic review of biobanks in Latin America: Strengths and limitations for biomedical research. Int J Biol Markers. 2024 Apr 13:3936155241239672. doi: 10.1177/03936155241239672. PMID: 38613331.
• Vargas-Vázquez A, Fermín-Martínez CA, Antonio-Villa NE, Fernández-Chirino L, Ramírez-García D, Dávila-López G, Díaz-Sánchez JP, Aguilar-Salinas CA, Seiglie JA, Bello-Chavolla OY. Insulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes. Atherosclerosis. 2024 Mar 13:117508. doi: 10.1016/j.atherosclerosis.2024.117508. PMID: 38570208.
• Sohail M, Palma-Martínez MJ, Chong AY, Quinto-Cortés CD, Barberena-Jonas C, Medina-Muñoz SG, Ragsdale A, Delgado-Sánchez G, Cruz-Hervert LP, Ferreyra-Reyes L, Ferreira-Guerrero E, Mongua-Rodríguez N, Canizales-Quintero S, Jimenez-Kaufmann A, Moreno-Macías H, Aguilar-Salinas CA, Auckland K, Cortés A, Acuña-Alonzo V, Gignoux CR, Wojcik GL, Ioannidis AG, Fernández-Valverde SL, Hill AVS, Tusié-Luna MT, Mentzer AJ, Novembre J, García-García L, Moreno-Estrada. Mexican Biobank advances population and medical genomics of diverse ancestries. Nature. 2023 Oct 11. doi: 10.1038/s41586-023-06560-0 

More information

Dr. Carlos Aguilar is an expert on the pathophysiology, treatment, and management of dyslipidemias and type 2 diabetes in Mexico. He is a surgeon specializing in Internal Medicine and Endocrinology and holds a doctorate in Medical Research. His main contributions include: participating in the identification of new genes involved in the pathophysiology of Familial Combined Hyperlipidemia; being part of the team that conducted the first genome-wide study to identify the genetic variants that modulate plasma lipid levels in Mexicans; and helping identify the R230C variant of the ABC-A1 transporter (a variant specific to Amerindian populations) as a determinant of HDL cholesterol concentrations in Mexicans, among others.

Since 1996, he has been deputy chief of the Department of Endocrinology and Metabolism of the National Institute of Medical Sciences and Nutrition (Mexico) and has been coordinator of the
Ethics Committee of the National Institute of Medical Sciences and Nutrition since 2012. He is also a member of the National Academy of Medicine and has held positions such as director of examinations of the Mexican Board of Endocrinology and president of the Mexican Society of Nutrition and Endocrinology. 

Carlos Aguilar is a Level III researcher with the National System of Researchers in Mexico and a Level F researcher with the National Institutes of Health in the U.S. His scientific output is prolific, with more than 540 articles published in peer-reviewed and/or indexed journals and 66,711 citations. His research focuses on the peculiarities of metabolic diseases in Mexican mestizos, such as the pathophysiology of primary dyslipidemias, the epidemiology of type 2 diabetes, the development of predictive models for type 2 diabetes and its comorbidities, and the characterization of the mechanisms by which certain genetic variants are associated with type 2 diabetes. He received Mexico’s National Science Award in 2018.

Carlos Aguilar joined Tecnológico de Monterrey as Distinguished Visiting Professor in Epidemiology at the School of Medicine and Health Sciences.

• Doctorate in Medical Research, Escuela Superior de Medicina, Instituto Politécnico Nacional
• Research stay at the Division of Atherosclerosis and Lipid Research, Washington University
• Specialty in Endocrinology, Instituto Nacional de la Nutrición
• Specialty in Internal Medicine, Instituto Nacional de la Nutrición
• Medical Surgeon, Universidad Nacional Autónoma de México (UNAM)

• Rojas-Martínez R, Escamilla-Nuñez C, Aguilar-Salinas CA, Castro-Porras L, Romero-Martínez M, Lazcano-Ponce E. Trends in the mortality of diabetes in Mexico from 1998 to 2022: a joinpoint regression and age-period-cohort effect analysis. Public Health. 2023 Dec 5;226:128-137. doi: 10.1016/j.puhe.2023.10.038
• Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, Rivera JA, Romero-Martinez M, Barquera S, Barrientos-Gutiérrez T. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Publica Mex. 2023 Jun 13;65:s163-s168. doi: 10.21149/14832
• Rojas-Martínez R, Escamilla-Núñez C, Castro-Porras L, Basto-Abreu A, Barrientos-Gutiérrez T, Romero-Martínez M, Aguilar-Salinas C. Tamizaje, prevalencia, diagnóstico previo, tratamiento y control de hipertensión, hipercolesterolemia y diabetes en adultos mexicanos. Ensanut 2022. Salud Publica Mex. 2023 Nov 13;65(6, nov-dic):685-696. doi: 10.21149/15060
• Rivera-Alcántara JA, Esparza-Hurtado N, Galán-Ramírez GA, Cruz-Bautista I, Mehta R, Aguilar-Salinas CA, Martagon AJ. A systematic review of biobanks in Latin America: Strengths and limitations for biomedical research. Int J Biol Markers. 2024 Apr 13:3936155241239672. doi: 10.1177/03936155241239672. PMID: 38613331.
• Vargas-Vázquez A, Fermín-Martínez CA, Antonio-Villa NE, Fernández-Chirino L, Ramírez-García D, Dávila-López G, Díaz-Sánchez JP, Aguilar-Salinas CA, Seiglie JA, Bello-Chavolla OY. Insulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes. Atherosclerosis. 2024 Mar 13:117508. doi: 10.1016/j.atherosclerosis.2024.117508. PMID: 38570208.
• Sohail M, Palma-Martínez MJ, Chong AY, Quinto-Cortés CD, Barberena-Jonas C, Medina-Muñoz SG, Ragsdale A, Delgado-Sánchez G, Cruz-Hervert LP, Ferreyra-Reyes L, Ferreira-Guerrero E, Mongua-Rodríguez N, Canizales-Quintero S, Jimenez-Kaufmann A, Moreno-Macías H, Aguilar-Salinas CA, Auckland K, Cortés A, Acuña-Alonzo V, Gignoux CR, Wojcik GL, Ioannidis AG, Fernández-Valverde SL, Hill AVS, Tusié-Luna MT, Mentzer AJ, Novembre J, García-García L, Moreno-Estrada. Mexican Biobank advances population and medical genomics of diverse ancestries. Nature. 2023 Oct 11. doi: 10.1038/s41586-023-06560-0 

More information

Dr. Armendáriz is recognized globally as one of the leading figures in the field of hepatology and as a pioneer in gene therapy. In addition to his contributions to Tecnológico de Monterrey, Dr. Armendáriz has collaborated for more than 25 years at the University of Guadalajara, where he became Full Professor "C", founder of the Department of Molecular Biology and Genomics, as well as founder and director of the Institute of Molecular Biology in Medicine at said university, one of the first programs in Mexico in what is now called Genomic Medicine. He has also been a visiting professor at the University of Florence, in Italy. 

A Level III Emeritus Researcher of the Mexican National System of Researchers, much of Dr. Armendáriz's research has focused on the cellular and molecular basis of the treatment of liver cirrhosis and renal glomerulosclerosis.

As a result of his research, he has published more than 200 scientific articles, has presented more than 470 papers in national and international congresses, and has played leadership roles in the National Commission for the Human Genome, the Mexican Academy of Science, and the National Academy of Medicine (Mexico).

Among the most relevant recognitions of his career is the National Science Award "Mario Molina", obtained in 2023. 

Dr. Armendáriz joined Tecnológico de Monterrey as a Distinguished Professor in Biomedical Sciences for the School of Medicine and Health Sciences. 

• Post-doctorate in Molecular Biology, University of Tennessee
• PhD Biochemistry, CINVESTAV, Instituto Politécnico Nacional 
• Master in Biochemistry, CINVESTAV, Instituto Politécnico Nacional

Dr. Armendáriz is recognized globally as one of the leading figures in the field of hepatology and as a pioneer in gene therapy. In addition to his contributions to Tecnológico de Monterrey, Dr. Armendáriz has collaborated for more than 25 years at the University of Guadalajara, where he became Full Professor "C", founder of the Department of Molecular Biology and Genomics, as well as founder and director of the Institute of Molecular Biology in Medicine at said university, one of the first programs in Mexico in what is now called Genomic Medicine. He has also been a visiting professor at the University of Florence, in Italy. 

A Level III Emeritus Researcher of the Mexican National System of Researchers, much of Dr. Armendáriz's research has focused on the cellular and molecular basis of the treatment of liver cirrhosis and renal glomerulosclerosis.

As a result of his research, he has published more than 200 scientific articles, has presented more than 470 papers in national and international congresses, and has played leadership roles in the National Commission for the Human Genome, the Mexican Academy of Science, and the National Academy of Medicine (Mexico).

Among the most relevant recognitions of his career is the National Science Award "Mario Molina", obtained in 2023. 

Dr. Armendáriz joined Tecnológico de Monterrey as a Distinguished Professor in Biomedical Sciences for the School of Medicine and Health Sciences. 

• Post-doctorate in Molecular Biology, University of Tennessee
• PhD Biochemistry, CINVESTAV, Instituto Politécnico Nacional 
• Master in Biochemistry, CINVESTAV, Instituto Politécnico Nacional

Dr. Richard Willson has an extensive career at the University of Houston, where he is Huffington-Woestemeyer Professor of Chemical and Biomolecular Engineering and Biochemistry. He is also Co-Principal Investigator of the U.S. FDA's Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC). He has been an affiliate in the Quantitative and Computational Biology program at Baylor College of Medicine since 2008 and a prominent senior affiliate member in the Cancer program at the Houston Methodist Research Institute since 2007. He was theme leader in Diagnostics at the NIH Western Regional Center of Excellence in Biodefense and Emerging Infectious Diseases.

Richard Willson’s work focuses on the development of diagnostics for infectious diseases and metabolic disorders and the development of new pharmaceuticals. He and his research group work on biomolecular recognition using monoclonal antibodies and aptamers. They explore the techniques of expression, mutagenesis, fluorescence anisotropy (kinetics), and titration calorimetry.

In the area of bioseparations, his recent work focuses on antibody purification. In the area of molecular diagnostics and sensors, he is using computer technology to identify viruses vs. human DNA. He is also working on a diagnostic that uses a method similar to glow-in-the-dark materials for easier home-based detection by ultra-sensitive lateral flow immunoassays.

Back in 2012 and due to his expertise in nucleic acid purification, he was selected to serve on the founding Technical Advisory Board of Moderna, Inc., which later developed the mRNA-based vaccine for COVID-19.

Richard Willson joined Tecnológico de Monterrey as a Distinguished Visiting Professor in Biotechnology Engineering for the Institute for Obesity Research and the School of Medicine and Health Sciences.

• Postdoctoral fellow, Biology, Massachusetts Institute of Technology (MIT)
• Ph.D., Chemical Engineering, Massachusetts Institute of Technology (MIT)
• M.Sc., Chemical Engineering, California Institute of Technology (Caltech)
   

• Goux, Heather & Vu, Binh & Wasden, Katherine & Alpadi, Kannan & Kumar, Ajay & Kalra, Bhanu & Savjani, Gopal & Brosamer, Kristen & Kourentzi, Katerina & Willson, Richard. (2023). Development of a quantitative fluorescence lateral flow immunoassay (LFIA) prototype for point-of-need detection of anti-Müllerian hormone. Practical Laboratory Medicine. 35. e00314. 10.1016/j.plabm.2023.e00314. 

• Lei, Rongwei & Vu, Binh & Kourentzi, Katerina & Soomro, Sanam & Danthanarayana, Adheesha & Brgoch, Jakoah & Nadimpalli, Suma & Petri, Michelle & Mohan, Chandra & Willson, Richard. (2022). A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. Frontiers in Immunology. 13. 10.3389/fimmu.2022.1044743.

• Nandy, Suman & Crum, Mary & Wasden, Katherine & Strych, Ulrich & Goyal, Atul & Maranholkar, Vijay & Mo, William & Vu, Binh & Kourentzi, Katerina & Willson, Richard. (2022). Protein A–Nanoluciferase fusion protein for generalized, sensitive detection of immunoglobulin G. Analytical Biochemistry. 660. 114929. 10.1016/j.ab.2022.114929. 

• Ortiz-Martinez, Margarita & González-González, Mirna & Martagon, Alexandro & Hlavinka, Victoria & Willson, Richard & Rito-Palomares, Marco. (2022). Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Current Diabetes Reports. 22. 10.1007/s11892-022-01453-4. 

• Chavan D, Chen H, Crum M, Vu B, Safari M, Smith M, Vekilov P, Conrad JC, Kourentzi K, Willson RC., "Neutral DNA-avidin nanoparticles as ultrasensitive reporters in immuno-PCR." Analyst. doi: 10.1039/d0an00134a., 2020

More information

Dr. Richard Willson has an extensive career at the University of Houston, where he is Huffington-Woestemeyer Professor of Chemical and Biomolecular Engineering and Biochemistry. He is also Co-Principal Investigator of the U.S. FDA's Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC). He has been an affiliate in the Quantitative and Computational Biology program at Baylor College of Medicine since 2008 and a prominent senior affiliate member in the Cancer program at the Houston Methodist Research Institute since 2007. He was theme leader in Diagnostics at the NIH Western Regional Center of Excellence in Biodefense and Emerging Infectious Diseases.

Richard Willson’s work focuses on the development of diagnostics for infectious diseases and metabolic disorders and the development of new pharmaceuticals. He and his research group work on biomolecular recognition using monoclonal antibodies and aptamers. They explore the techniques of expression, mutagenesis, fluorescence anisotropy (kinetics), and titration calorimetry.

In the area of bioseparations, his recent work focuses on antibody purification. In the area of molecular diagnostics and sensors, he is using computer technology to identify viruses vs. human DNA. He is also working on a diagnostic that uses a method similar to glow-in-the-dark materials for easier home-based detection by ultra-sensitive lateral flow immunoassays.

Back in 2012 and due to his expertise in nucleic acid purification, he was selected to serve on the founding Technical Advisory Board of Moderna, Inc., which later developed the mRNA-based vaccine for COVID-19.

Richard Willson joined Tecnológico de Monterrey as a Distinguished Visiting Professor in Biotechnology Engineering for the Institute for Obesity Research and the School of Medicine and Health Sciences.

• Postdoctoral fellow, Biology, Massachusetts Institute of Technology (MIT)
• Ph.D., Chemical Engineering, Massachusetts Institute of Technology (MIT)
• M.Sc., Chemical Engineering, California Institute of Technology (Caltech)
   

• Goux, Heather & Vu, Binh & Wasden, Katherine & Alpadi, Kannan & Kumar, Ajay & Kalra, Bhanu & Savjani, Gopal & Brosamer, Kristen & Kourentzi, Katerina & Willson, Richard. (2023). Development of a quantitative fluorescence lateral flow immunoassay (LFIA) prototype for point-of-need detection of anti-Müllerian hormone. Practical Laboratory Medicine. 35. e00314. 10.1016/j.plabm.2023.e00314. 

• Lei, Rongwei & Vu, Binh & Kourentzi, Katerina & Soomro, Sanam & Danthanarayana, Adheesha & Brgoch, Jakoah & Nadimpalli, Suma & Petri, Michelle & Mohan, Chandra & Willson, Richard. (2022). A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. Frontiers in Immunology. 13. 10.3389/fimmu.2022.1044743.

• Nandy, Suman & Crum, Mary & Wasden, Katherine & Strych, Ulrich & Goyal, Atul & Maranholkar, Vijay & Mo, William & Vu, Binh & Kourentzi, Katerina & Willson, Richard. (2022). Protein A–Nanoluciferase fusion protein for generalized, sensitive detection of immunoglobulin G. Analytical Biochemistry. 660. 114929. 10.1016/j.ab.2022.114929. 

• Ortiz-Martinez, Margarita & González-González, Mirna & Martagon, Alexandro & Hlavinka, Victoria & Willson, Richard & Rito-Palomares, Marco. (2022). Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Current Diabetes Reports. 22. 10.1007/s11892-022-01453-4. 

• Chavan D, Chen H, Crum M, Vu B, Safari M, Smith M, Vekilov P, Conrad JC, Kourentzi K, Willson RC., "Neutral DNA-avidin nanoparticles as ultrasensitive reporters in immuno-PCR." Analyst. doi: 10.1039/d0an00134a., 2020

More information

Dr. Steven Popper is a professor of Science and Technology Policy at the Pardee RAND Graduate School. He was a senior economist at RAND Corporation in the U.S., a nonprofit institution that develops innovative solutions to public policy challenges and decision-making problems. Steven Popper served as associate director of the Science and Technology Policy Institute, where he directed studies on critical technology issues for the White House (1996-2001), and also served as chair of the Industrial Science and Technology section of the American Association for the Advancement of Science (AAAS). In addition, he has also served on several academic and international boards and has been a consultant to the World Bank and the OECD.

He was co-founder and chief operating officer of Evolving Logic Inc., a company that developed the revolutionary Computer Assisted Reasoning (CARs) system and a methodology called RAP™ (Robust Adaptive Planning) for complex decision making. He was the founding chair for education and training of the Society for Decision Making Under Deep Uncertainty (DMDU) and is currently the Society’s chair for finance.

His areas of expertise include strategy under uncertainty, foresight methodology, and emerging technologies, to name a few. His research experience includes strategy, planning, and decision making under deep uncertainty; national science and technology policy; technology-based regional economic development; economic system transitions; and international security and defense, among others.

Steven Popper joined Tecnológico de Monterrey as a Distinguished University Professor in Decision Sciences for the School of Social Sciences and Government and the School of Government and Public Transformation.

• Ph.D., Economics, University of California, Berkeley
• B.Sc., Biochemistry, University of Minnesota

• Systematic Method for Prioritizing Investments in Game-Changing Technologies: The Evaluation and Comparison Process Framework, with Richard Silberglitt, Cynthia R. Cook, Lisa Pelled Colabella, Paul Dreyer, Eric Hastings, Alexander C. Hou, Alexis Levedahl, Edward Parker, Scott Savitz, and Li Ang Zhang, RAND Corporation, RR-A632-1, 2022.

• Use of Predictive Analytic Tools to Assess Technological Emergences and Acquisition Targets, with Richard Silberglitt, Anna Jean Wirth, Christopher A. Eusebi, Inez Khan, Jasmin Léveillé. RAND Corporation, RR-A539-2, 2022

• Decision Making under Deep Uncertainty: From Theory to Practice, with Vincent A. W. J. Marchau, Warren E. Walker, Pieter J. T. M. Bloemen (eds.), Springer International Publishing (10.1007/978-3-030-05252-2), 2019.

• “Designing a Robust Decision–Based National Security Policy Process: Strategic Choices for Uncertain Times”, in Frank, A.B. and E.M. Bartels (eds.), Adaptive Engagement for Undergoverned Spaces: Concepts, Challenges, and Prospects for New Approaches, 2022.

• “Forecasts and decisions: A commentary on Lustick and Tetlock”, with Robert J. Lempert, Paul K. Davis, Tim McDonald, in Futures and Foresight Science 3 (2), June 2021. https://doi.org/10.1002/ffo2.81 <https://onlinelibrary.wiley.com/doi/10.1002/ffo2.81>

• China's Propensity for Innovation in the 21st Century: Identifying Indicators of Future Outcomes, with Marjory S. Blumenthal, Eugeniu Han, Sale Lilly, Lyle J. Morris, Caroline S. Wagner, Christopher A. Eusebi, Brian G. Carlson, and Alice Shih, RAND Corporation, RR-A208-1, 2020.

More information

Dr. Steven Popper is a professor of Science and Technology Policy at the Pardee RAND Graduate School. He was a senior economist at RAND Corporation in the U.S., a nonprofit institution that develops innovative solutions to public policy challenges and decision-making problems. Steven Popper served as associate director of the Science and Technology Policy Institute, where he directed studies on critical technology issues for the White House (1996-2001), and also served as chair of the Industrial Science and Technology section of the American Association for the Advancement of Science (AAAS). In addition, he has also served on several academic and international boards and has been a consultant to the World Bank and the OECD.

He was co-founder and chief operating officer of Evolving Logic Inc., a company that developed the revolutionary Computer Assisted Reasoning (CARs) system and a methodology called RAP™ (Robust Adaptive Planning) for complex decision making. He was the founding chair for education and training of the Society for Decision Making Under Deep Uncertainty (DMDU) and is currently the Society’s chair for finance.

His areas of expertise include strategy under uncertainty, foresight methodology, and emerging technologies, to name a few. His research experience includes strategy, planning, and decision making under deep uncertainty; national science and technology policy; technology-based regional economic development; economic system transitions; and international security and defense, among others.

Steven Popper joined Tecnológico de Monterrey as a Distinguished University Professor in Decision Sciences for the School of Social Sciences and Government and the School of Government and Public Transformation.

• Ph.D., Economics, University of California, Berkeley
• B.Sc., Biochemistry, University of Minnesota

• Systematic Method for Prioritizing Investments in Game-Changing Technologies: The Evaluation and Comparison Process Framework, with Richard Silberglitt, Cynthia R. Cook, Lisa Pelled Colabella, Paul Dreyer, Eric Hastings, Alexander C. Hou, Alexis Levedahl, Edward Parker, Scott Savitz, and Li Ang Zhang, RAND Corporation, RR-A632-1, 2022.

• Use of Predictive Analytic Tools to Assess Technological Emergences and Acquisition Targets, with Richard Silberglitt, Anna Jean Wirth, Christopher A. Eusebi, Inez Khan, Jasmin Léveillé. RAND Corporation, RR-A539-2, 2022

• Decision Making under Deep Uncertainty: From Theory to Practice, with Vincent A. W. J. Marchau, Warren E. Walker, Pieter J. T. M. Bloemen (eds.), Springer International Publishing (10.1007/978-3-030-05252-2), 2019.

• “Designing a Robust Decision–Based National Security Policy Process: Strategic Choices for Uncertain Times”, in Frank, A.B. and E.M. Bartels (eds.), Adaptive Engagement for Undergoverned Spaces: Concepts, Challenges, and Prospects for New Approaches, 2022.

• “Forecasts and decisions: A commentary on Lustick and Tetlock”, with Robert J. Lempert, Paul K. Davis, Tim McDonald, in Futures and Foresight Science 3 (2), June 2021. https://doi.org/10.1002/ffo2.81 <https://onlinelibrary.wiley.com/doi/10.1002/ffo2.81>

• China's Propensity for Innovation in the 21st Century: Identifying Indicators of Future Outcomes, with Marjory S. Blumenthal, Eugeniu Han, Sale Lilly, Lyle J. Morris, Caroline S. Wagner, Christopher A. Eusebi, Brian G. Carlson, and Alice Shih, RAND Corporation, RR-A208-1, 2020.

More information

Dr. Ernesto Stein was the Inter-American Development Bank (IDB) representative in Mexico, where he guided all the activities of the IDB Group (public and private side) in the country with a focus on reducing regional gaps and fostering economic development. With a career spanning almost 30 years at the IDB, Ernesto Stein held different roles, including principal economist at the Research Department and regional economic advisor for Central America, Mexico, Panama, and the Dominican Republic.

He has also been a Growth Fellow at Harvard University’s Center for International Development.

His research primarily focuses on areas critical to economic development and policy. These include international trade and integration, foreign direct investment, productive development policies, institutional economics, and political economy.

He has authored or edited over 12 books and contributed to more than 40 articles in edited volumes and refereed journals such as the Journal of International Economics, the Journal of Development Economics, Economic Policy, Economics and Politics, and the American Economic Review (papers and proceedings), among others.

Ernesto Stein joined Tecnológico de Monterrey as Distinguished University Professor in Public Policy for the School of Social Sciences and Government and the School of Government and Public Transformation.

• Ph.D., Economics, University of California, Berkeley
• B.A., Economics, University of Buenos Aires

• Ghezzi, P., Hallak, JC., Stein, E, Ordoñez, R. and Salazar, L., 2022, Competing in Agribusiness: Corporate Strategies and Public Policies for the Challenges of the 21st Century, Inter-American Development Bank

• Rodriguez Chatruc, M., Stein, E. and Vlaicu, R., 2021, “How Issue Framing Shapes Trade Attitudes”: Evidence from a multi-country survey experiment”, Journal of International Economics 129.

• Crespi, G., Fernández-Arias, E., and Stein, E., eds., 2014. Rethinking Productive Development: Sound Policies and Institutions for Economic Transformation. Inter-American Development Bank.

• Daude, C. and Stein, E., 2007. The quality of institutions and foreign direct investment. Economics & Politics, 19(3), pp.317-344.

• Alesina, A., Hausmann, R., Hommes, R. and Stein, E., 1999. Budget institutions and fiscal performance in Latin America. Journal of Development Economics, 59(2), pp.253-273.

More information

Dr. Ernesto Stein was the Inter-American Development Bank (IDB) representative in Mexico, where he guided all the activities of the IDB Group (public and private side) in the country with a focus on reducing regional gaps and fostering economic development. With a career spanning almost 30 years at the IDB, Ernesto Stein held different roles, including principal economist at the Research Department and regional economic advisor for Central America, Mexico, Panama, and the Dominican Republic.

He has also been a Growth Fellow at Harvard University’s Center for International Development.

His research primarily focuses on areas critical to economic development and policy. These include international trade and integration, foreign direct investment, productive development policies, institutional economics, and political economy.

He has authored or edited over 12 books and contributed to more than 40 articles in edited volumes and refereed journals such as the Journal of International Economics, the Journal of Development Economics, Economic Policy, Economics and Politics, and the American Economic Review (papers and proceedings), among others.

Ernesto Stein joined Tecnológico de Monterrey as Distinguished University Professor in Public Policy for the School of Social Sciences and Government and the School of Government and Public Transformation.

• Ph.D., Economics, University of California, Berkeley
• B.A., Economics, University of Buenos Aires

• Ghezzi, P., Hallak, JC., Stein, E, Ordoñez, R. and Salazar, L., 2022, Competing in Agribusiness: Corporate Strategies and Public Policies for the Challenges of the 21st Century, Inter-American Development Bank

• Rodriguez Chatruc, M., Stein, E. and Vlaicu, R., 2021, “How Issue Framing Shapes Trade Attitudes”: Evidence from a multi-country survey experiment”, Journal of International Economics 129.

• Crespi, G., Fernández-Arias, E., and Stein, E., eds., 2014. Rethinking Productive Development: Sound Policies and Institutions for Economic Transformation. Inter-American Development Bank.

• Daude, C. and Stein, E., 2007. The quality of institutions and foreign direct investment. Economics & Politics, 19(3), pp.317-344.

• Alesina, A., Hausmann, R., Hommes, R. and Stein, E., 1999. Budget institutions and fiscal performance in Latin America. Journal of Development Economics, 59(2), pp.253-273.

More information